Skip to content

Exploration the effects of Elimination of Pathogens Through Purgation and Diuresis on bronchial asthma of children based on intestinal microecology

Exploration the effects of Elimination of Pathogens Through Purgation and Diuresis on bronchial asthma of children based on intestinal microecology

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002810
Enrollment
Unknown
Registered
2019-12-07
Start date
2020-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Sponsors

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Children with asthma (1) All the children were in accordance with the diagnostic standard of asthma; (2) The age was 5-14 years old; (3) No standardized treatment such as bronchodilator was received within 48 hours before being included in the study; (4) The children could be followed up for 3 months; (5) The children had good compliance and could cooperate with the examination of pulmonary ventilation function; (6) The parents of the children or their legal guardians sign the informed consent form; the children = 8 years old need to sign both the children and their families. 2. Healthy children (1) The age was 5-14 years old; (2) No history of asthma and allergy; (3) No infection and medication history within 1 month before enrollment; (4) The parents of the children or their legal guardians sign the informed consent form; the children = 8 years old need to sign both the children and their families.

Exclusion criteria

Exclusion criteria: (1) Children who are allergic to or have contraindications to standardized drugs; (2) Children with chronic lung disease, pneumonia, pneumothorax and other children who significantly affect lung function parameters, or children with serious primary diseases and psychosis with heart, liver, kidney and hematopoiesis; (3) Children participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Serum IgE;16S rDNA of feces;Metabolism of feces;ACT/ C-ACT;PFTs;

Countries

China

Contacts

Public ContactYoupeng Wang
wangyp8899@163.com+86 13604808899

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026